Sign up for a free trial now

Login
Subscribe
Take a FREE Trial

About Us
Contact us
RSS

22 May 2013

Search

The Pharma Letter

Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe

Xerese Articles

Medivir renegotiates deal with Meda, receiving $45 million for US rights for Xerese; Meda passes this and Elidel to Valeant

30 June 2011

Showing 1-1 of 1 articles

Go to beginning

Previous

1

Next

Go to end

Hot Topics
Most Read

Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

© 2013 thepharmaletter.com

Home
RSS
About Us
Subscribe
Terms and Conditions
Article Archive

Site powered by WORKSsitebuilder CMS